Takeda Pharmaceutical Company Limited (TAK)
NYSE: TAK · Real-Time Price · USD
17.99
+0.13 (0.70%)
Mar 24, 2026, 11:00 AM EDT - Market open
Takeda Pharmaceutical Revenue
Takeda Pharmaceutical had revenue of 1.19T JPY in the quarter ending December 31, 2025. This brings the company's revenue in the last twelve months to 4.52T, down -5.56% year-over-year. In the fiscal year ending March 31, 2025, Takeda Pharmaceutical had annual revenue of 4.58T with 7.45% growth.
Revenue (ttm)
4.52T JPY
Revenue Growth
-5.56%
P/S Ratio
1.98
Revenue / Employee
95,203,877 JPY
Employees
47,455
Market Cap
56.82B USD
Revenue Chart
* This company reports financials in JPY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 4.58T | 317.79B | 7.45% |
| Mar 31, 2024 | 4.26T | 236.28B | 5.87% |
| Mar 31, 2023 | 4.03T | 458.47B | 12.85% |
| Mar 31, 2022 | 3.57T | 371.19B | 11.61% |
| Mar 31, 2021 | 3.20T | -93.38B | -2.84% |
| Mar 31, 2020 | 3.29T | 1.19T | 56.93% |
| Mar 31, 2019 | 2.10T | 326.69B | 18.45% |
| Mar 31, 2018 | 1.77T | 38.48B | 2.22% |
| Mar 31, 2017 | 1.73T | -75.33B | -4.17% |
| Mar 31, 2016 | 1.81T | 29.55B | 1.66% |
| Mar 31, 2015 | 1.78T | 86.14B | 5.09% |
| Mar 31, 2014 | 1.69T | 134.68B | 8.65% |
| Mar 31, 2013 | 1.56T | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Teva Pharmaceutical Industries | 17.26B |
| Haleon | 14.85B |
| Viatris | 14.30B |
| Zoetis | 9.47B |
| Elanco Animal Health | 4.72B |
| Dr. Reddy's Laboratories | 3.85B |
| United Therapeutics | 3.18B |
| Neurocrine Biosciences | 2.86B |
TAK News
- 5 days ago - TrumpRx lists many medicines at prices higher than paid in UK - Reuters
- 19 days ago - Takeda Pharmaceutical Company Limited (TAK) Presents at TD Cowen 46th Annual Health Care Conference Transcript - Seeking Alpha
- 19 days ago - Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2025 Financial Results - Benzinga
- 22 days ago - Takeda and Protagonist Announce U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Rusfertide as a Potential First-in-Class Therapy for Polycythemia Vera - Business Wire
- 4 weeks ago - Positive Phase 3 Data Demonstrate Potential for ENTYVIO® (vedolizumab) to Address Treatment Gap for Children and Adolescents with Moderate to Severe Ulcerative Colitis - Business Wire
- 6 weeks ago - U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Takeda's Oveporexton (TAK-861) as a Potential First-in-Class Therapy for Narcolepsy Type 1 - Business Wire
- 6 weeks ago - Takeda Taps AI Startup Iambic In $1.7 Billion+ Deal To Speed Up Drug Discovery - Benzinga
- 6 weeks ago - Takeda deepens AI drug discovery push with $1.7 billion Iambic deal - Reuters